Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
Corbus Pharmaceuticals Holdings, Inc. Common Stock
Corbus Pharmaceuticals Holdings Inc is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases.
IPO Date: November 1, 2014
Sector: Healthcare
Industry: Biotech
Market Cap: $89.33M
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.31 | 3.90%
Avg Daily Range (30 D): $0.29 | 3.67%
Avg Daily Range (90 D): $0.27 | 3.92%
Institutional Daily Volume
Avg Daily Volume: 1.29M
Avg Daily Volume (30 D): .13M
Avg Daily Volume (90 D): .14M
Trade Size
Avg Trade Size (Sh.): 252
Avg Trade Size (Sh.) (30 D): 63
Avg Trade Size (Sh.) (90 D): 64
Institutional Trades
Total Inst.Trades: 433
Avg Inst. Trade: $1.78M
Avg Inst. Trade (30 D): $2.83M
Avg Inst. Trade (90 D): $2.32M
Avg Inst. Trade Volume: .04M
Avg Inst. Trades (Per Day): 1
Market Closing Trades
Avg Closing Trade: $2.08M
Avg Closing Trade (30 D): $6.62M
Avg Closing Trade (90 D): $3.7M
Avg Closing Volume: 44.19K
   
News
Jul 10, 2025 @ 5:00 PM
Cannabinoid Agonist Clinical Trial Pipeline Appear...
Source: Delveinsight
May 22, 2025 @ 12:00 PM
Corbus Pharmaceuticals to Present at the Jefferies...
Source: N/A
Jun 1, 2024 @ 2:00 PM
SYS6002 (CRB-701) A Next-Generation Nectin-4 Targe...
Source: Corbus Pharmaceuticals Holdings, Inc.
May 23, 2024 @ 9:05 PM
Updated Phase 1 Clinical Data for SYS-6002 (CRB-70...
Source: Corbus Pharmaceuticals Holdings, Inc.
May 14, 2024 @ 5:32 PM
Will Pharma And Healthcare Have Competitive Edge I...
Source: Nicolás Jose Rodriguez
Financials
  TTM Q1 2025 Q4 2024
Basic EPS $-4.2 $-1.39 $-.76
Diluted EPS $-4.2 $-1.39 $-.76
Revenue $ 7.33M $ 1.68M $ 3.55M
Gross Profit $ $ $
Net Income / Loss $ -50.29M $ -16.98M $ -9.53M
Operating Income / Loss $ -58.87M $ -19.78M $ -12.61M
Cost of Revenue $ $ $
Net Cash Flow $ 3.1M $ M $ -2.23M
PE Ratio    
Splits
Feb 14, 2023:   1:30